J. Carles

Sweet's Syndrome and Acute Myelogenous Leukemia

C. Ferrándiz, A. Flores, M. Ribera, 1990, International journal of dermatology.

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

R. Rosell, A. Abad, N. Ribelles, 1992, Investigational New Drugs.

Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness

J. Morote, I. de Torres, J. Reventós, 2014, International journal of molecular sciences.

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

B. Tombal, C. Sternberg, B. Melichar, 2021, ESMO open.

612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

A. Tafreshi, S. Oudard, G. Gravis, 2021, Annals of Oncology.